JC
Joshua Casan
The University of Melbourne, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre
Research areas: Biochemistry, Genetics and Molecular Biology · Molecular Biology · Lymphoma Diagnosis and Treatment · CRISPR and Genetic Engineering · RNA Interference and Gene Delivery
0000-0002-4322-8561
Employment
-
The University of Melbourne Honorary Conjoint Senior Fellow
-
Peter MacCallum Cancer Centre Consultant Haematologist
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (40)
- Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition Save
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics Save
- Novel chimeric PD-L1::PD-L2 fusion and immune evasion in lymphoma Save
- On the RAdR in relapsed T-cell lymphoma Save
- Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma Save
- Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets Save
- Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options Save
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics Save
- Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial Save
- Development of a novel CAR-T cell therapy using a multimodal approach to target T cell lymphoma Save
- Efficient mRNA delivery to resting T cells to reverse HIV latency Save
- Heterozygous germline TET2 loss-of-function variants associated with an ALPS-like phenotype Save
- Immune pathways, current and potential therapies in Mycosis fungoides and Sezary syndrome Save
- Marked Erythroblast Haemophagocytosis in Association With Immunotherapy for Metastatic Melanoma Save
- Refinement of the Classification of DDX41 Variants Through Analysis of Aggregated Clinical Datasets Save
- Systematic silencing of oncogenic fusion transcripts with ultra-precise CRISPR-Cas13b Save
- Degraders upgraded: the rise of PROTACs in hematological malignancies Save
- Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision Save
- Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing Save
- Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon Save